身体活动,饮食和患阿尔茨海默病的风险
Nikolaos Scarmeas1, Jose A Luchsinger, Nicole Schupf
1Taub Institute for Research in Alzheimer's Disease and the Aging Brain and Department of Neurology, Columbia University Medical Center, 622 W 168th St, New York, NY 10032, USA. ns257@columbia.edu
JAMA
|August 13, 2009
概括
坚持地中海式饮食和定期体育活动显著降低了阿尔茨海默病 (AD) 风险. 结合这两种生活方式因素,可以对阿尔茨海默病的发展产生保护作用.
科学领域:
- 神经科学是一个神经科学.
- 流行病学 流行病学
- 老年学是指老年学的学科.
背景情况:
- 阿尔茨海默病 (AD) 风险受生活方式因素的影响.
- 地中海式饮食和体育活动独立地与降低AD风险有关.
- 饮食和体育活动对AD风险的综合影响仍未得到充分研究.
研究的目的:
- 检查地中海型饮食的坚持和身体活动水平与阿尔茨海默病风险之间的协同关系.
- 为了确定组合的生活方式干预措施是否比单个组件提供更好的防治AD.
主要方法:
- 一项前性队列研究,涉及1880名认知完整的老人.
- 用经过验证的措施评估饮食坚持和体力活动水平.
- 考克斯的比例危险模型分析了发生阿尔茨海默病的时间,并调整了共变量.
主要成果:
- 对地中海型饮食的更高坚持与AD风险显著降低有关 (HR=0.60对高坚持).
- 增加的体力活动水平也独立地与较低的AD风险相关 (HR=0.67对于高活动).
- 坚持高饮食和高身体活动的个体显示,阿尔茨海默病的绝对风险大幅降低 (12%与19%).
结论:
- 坚持地中海式饮食和身体活动都与降低阿尔茨海默病风险有关.
- 健康饮食和定期运动的结合可能会对阿尔茨海默病产生协同保护作用.
- 这些发现支持生活方式干预,以预防阿尔茨海默病.
相关概念视频
Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Dementia
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
The progression of dementia is generally gradual.
Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
